Leonard S. Schleifer, M.D., Ph.D., is a distinguished figure in the biotechnology industry, currently serving as the Board co-Chair, President, and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. Born in 1953, Schleifer completed his undergraduate studies at Cornell University, earning a Bachelor of Arts degree in 1973. He then pursued a medical degree at the University of Virginia School of Medicine, graduating in 1977, and later obtained a Ph.D. in Pharmacology from the same institution in 1981. Schleifer's early career included a stint as a resident in neurology at Weill Cornell Medical Center, where he also served as an assistant professor of neurology. Schleifer co-founded Regeneron Pharmaceuticals in 1988 with a vision to develop novel medicines that address serious medical needs. Under his leadership, Regeneron has grown into a leading biotechnology company known for its innovative approach to drug discovery and development. One of the company's flagship products, EYLEA (aflibercept), has become a cornerstone treatment for various retinal diseases. Additionally, Regeneron has made significant strides in the development of treatments for conditions such as atopic dermatitis, asthma, and various cancers. Schleifer's strategic foresight and commitment to scientific excellence have been instrumental in driving the company's success, earning him recognition as a visionary leader in the biotech sector. In his role as President and CEO, Schleifer oversees the company's operations and strategic direction, ensuring that Regeneron remains at the forefront of medical innovation. His leadership has been pivotal in fostering a culture of scientific rigor and collaboration within the company. Schleifer's achievements extend beyond Regeneron; he has been an active member of several professional organizations, including the Biotechnology Innovation Organization (BIO), where he has served on the board of directors. His contributions to the field have been recognized with numerous awards and honors, reflecting his enduring impact on the biotechnology landscape.